MTOR and cancer: This strategy has allowed accurate prospective identification of cancer cells sensitive to the pan-Class I PI3K agent pictilisib (false-discovery rate or FDR < 10−10) and the dual class I PI3K/mTOR drug GDC-0980 (FDR < 0.0019), as well as other targeted agents in a large panel of cancer cell lines [56].